60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasisMarch 10, 2016Psoriasis
ACR: Cardiovascular risk factors in psoriatic diseases are common, often go untreatedDecember 1, 2015Psoriasis
